Journal of Allergy and Clinical Immunology: Global (Nov 2024)

Effect of benralizumab on inflammation in skin after intradermal allergen challenge in patients with moderate-to-severe atopic dermatitis

  • Christiane E. Whetstone, BSc,
  • Ruth P. Cusack, MB, MPH,
  • Emma Price, MSc,
  • Karen Howie,
  • Catie Stevens, BSc,
  • Dhuha Al-Sajee, MD, PhD,
  • Sue Beaudin, BSc,
  • Jennifer Wattie,
  • Nadia Alsaji, MBChB,
  • Abbey Schlatman, BSc,
  • Vanessa Luk, BHSc,
  • Xiaotian Ju, PhD,
  • Paul O’Byrne, MB,
  • Mark Inman, MD, PhD,
  • Roma Sehmi, PhD,
  • Hermenio Lima, MD, PhD,
  • Gail M. Gauvreau, PhD

Journal volume & issue
Vol. 3, no. 4
p. 100310

Abstract

Read online

Background: Atopic dermatitis (AD) is a skin barrier dysfunction characterized by tissue eosinophilia. Objective: In patients with AD, we evaluated the effect of eosinophil depletion with benralizumab on markers of inflammation in skin after intradermal allergen challenge. Methods: A total of 20 patients with moderate-to-severe AD completed a randomized, double-blind, placebo-controlled parallel-group study comparing 3 doses of benralizumab (30 mg each) administered subcutaneously every 4 weeks (n = 9) with placebo (n = 11). Allergen and saline control intradermal challenges were conducted before and after treatment, with skin biopsy samples collected 24 hours after challenge. Early and late cutaneous responses were measured by skin wheal size. Levels of eosinophils and IL-5 receptor-α–bearing cells, including eosinophil progenitor (EoP) cells, basophils, and mast cells, in papillary dermis were measured by immunofluorescence microscopy, and levels of EoP cells, hematopoietic progenitor cells, and type 2 innate lymphoid cells in the blood were measured by flow cytometry. Outcomes were compared between the placebo and benralizumab treatment groups by using the Mann-Whitney U test. Results: Benralizumab reduced eosinophil counts in the blood (P < .0001) and allergen-challenged skin, as measured by hematoxylin and eosin staining and eosinophil cationic protein antibody concentration (P < .05). Benralizumab lowered the levels of EoP cells, mast cells, and basophils in the skin, as well as the levels of EoP cells, hematopoietic progenitor cells, and type 2 innate lymphoid cells in the blood (all P < .05). There was a trend toward improvement in the early cutaneous response (P = .095) but no effect on the late cutaneous response. Conclusion: In patients with moderate-to-severe AD, benralizumab treatment significantly inhibited accumulation of eosinophils and other IL-5 receptor-α–expressing cells in the papillary dermis after intradermal allergen challenge. Targeting IL-5 receptor-α–positive cells did not modulate the size of the allergen-induced skin wheal (ClincialTrials.gov identifier NCT03563066).

Keywords